Safety and Immunogenicity of MAGEA 3 Cancer Immunotherapeutic
- Slides: 4
Safety and Immunogenicity of MAGE-A 3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A 3 -Positive Non-Small-Cell Lung Cancer Jean-Louis Pujol, MD, Ph. D, Johan F. Vansteenkiste, MD, Ph. D, Tommaso Martino De Pas, MD, Djordje Atanackovic, MD, Martin Reck, MD, Ph. D, Michiel Thomeer, MD, Ph. D, Jean-Yves Douillard, MD, Ph. D, Gianpiero Fasola, MD, Vanessa Potter, MD, Ph. D, Paul Taylor, MD, Lionel Bosquée, MD, Robert Scheubel, MD, Silvija Jarnjak, MD, Muriel Debois, MSc, Pedro de Sousa Alves, Ph. D, Jamila Louahed, Ph. D, Vincent G. Brichard, MD, Ph. D, Frédéric F. Lehmann, MD, Ph. D Journal of Thoracic Oncology Volume 10 Issue 10 Pages 1458 -1467 (October 2015) DOI: 10. 1097/JTO. 0000000653 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Journal of Thoracic Oncology 2015 101458 -1467 DOI: (10. 1097/JTO. 0000000653) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Journal of Thoracic Oncology 2015 101458 -1467 DOI: (10. 1097/JTO. 0000000653) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 Journal of Thoracic Oncology 2015 101458 -1467 DOI: (10. 1097/JTO. 0000000653) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions
